Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.
A pooled analysis of two trials presented at the AACR Annual Meeting looked at the use of pembrolizumab in patients with heavily pretreated extensive small-cell lung cancer.
A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.
A series of communication-focused interventions were implemented to try to improve conversations about values, goals, and preferences with patients with life-limiting cancer.
In this study, researchers aimed to further characterize differences in hospice use in a cohort of ovarian cancer patients.
A randomized trial tested whether lymphadenectomy would improve survival outcomes in patients with advanced ovarian cancer.
A single-center evaluation of the FDA's Expanded Access program indicated broad use of the program among the center’s patients, including a large percentage of pediatric patients.
The FDA has granted Priority Review to Celgene’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma.